Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.98

-2.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Young who wrote (10717)	2/29/2004 3:46:48 PM
From: quidditch	Read Replies (1) of 52153

Mike, Rick, sales, Peter and others follow this closely. I recall estimates that indiplon NDA would be filed anywhere from six months to one year after FDA action on estorra. I just checked the NBIX website and (somewhat shockingly) it does not appear to have been updated recently: still refers to an NDA by year-end 2003 and reports on progress on the malignant glioma candidate (still in NBIX of course but to be out-licensed or otherwise disposed of). My guess is that, with multiple P3s concluding, it will be by the end of this year. A technical question: in the IR and MR forms of indiplon, can that be encompassed by one application or do the two release formulations require separate NDAs? quid

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next